At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Germany based CFO’ operating in the Pharmaceutical space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Thomas Dürre
Chief Financial Officer of Isotopen Technologien München
Thomas accepted the position as Chief Financial Officer at ITM Isotopen Technologien München AG in April 2016. Before that he worked for 3 years as Senior Vice President at Software AG and was responsible for all aspects of Global Integration Management. Prior to this he was CFO at alfabet AG for 15 years and headed the successful sale and merger of alfabet AG to Software AG. Thomas started his career in 1991 at Ernst & Young and worked from 1996 until 1998 as Controller Germany for the US based international waste management company BFI. Thomas has 25 years of work experience in finance, especially in the international expansion and growth of start-ups and preparation as well as execution of exit strategies in private equity companies. He holds a Masters Degree in Business Administration (Dipl.-Kfm.) from the University of Cologne (Germany).
Follow Thomas Dürre:
About Isotopen Technologien München: Isotopen Technologien München is a privately held biotechnology and radiopharmaceutical group of companies.
Thomas Hoffmann
Chief Financial Officer of Phenex Pharmaceuticals
Follow Thomas Hoffmann:
About Phenex Pharmaceuticals: Phenex Pharmaceuticals is a drug discovery and development company focused on developing novel pharmaceuticals.
Oliver Schlüter
Managing Director and CFO of Novaliq
Oliver Schlüter is managing director, CFO of Novaliq. He has 20+ years of professional experience within the fields of Finance and Life Sciences. Oliver Schlüter was CFO of CureVac GmbH from 2010 to 2015. During his tenure at CureVac, he was instrumental in the transformation of a 70 employee R&D-driven company to a 170-employee customer-centric and value-focused corporation that entered into several strategic partnerships with in-house cGMP-manufacturing. From the time of his appointment in 2010, the company secured more than USD 250 million in funding and increased the company value more than tenfold to more than €1 billion. He holds a PhD in computational finance and also studied business administration.
Follow Oliver Schlüter:
About Novaliq: Novaliq is a pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics.
Christian Nafe
Managing Director and Chief Financial Officer of leon nanodrugs
Christian Nafe is the Managing Director & Chief Financial Officer of leon-nanodrugs.He brings in more than 25 years of successfully working in corporate finance, controlling and finance. Christian held leading management positions in different roles in worldwide operating companies, since 2000 with a focus on life sciences. During this time, he successfully managed numerous license contracts, asset and share deals as well as supply agreements. He recently served as CEO/CFO at BioNet Holding GmbH, BioNet Ventures GmbH and BioNet Pharma GmbH (former Scil Technology GmbH). Christian graduated with honors as Dipl. Kaufmann in Business Administration from University Regensburg.
Follow Christian Nafe:
About leon nanodrugs: leon-nanodrugs is a nanotechnology-based drug development company.
Thomas Pfaadt
CFO and Managing Director of c-LEcta
Thomas joined c-LEcta in 2018 as CFO and managing director. Previously he worked for a private equity owned operator of rehabilitation clinics in Berlin as well as for a family owned integrated healthcare group and was responsible for M&A respectively for corporate finance and investor relations. Before that he gained experiences as banker and consultant with a strong focus on the healthcare sector. Thomas studied business administration at Goethe University in Frankfurt/M and at University of Southampton/UK.
Follow Thomas Pfaadt:
About c-LEcta: c-LEcta operates as a biotechnology company focusing on enzyme engineering and bioprocess development for regulated markets.
Thomas Pfaadt
CFO and Managing Director of c-LEcta
Thomas joined c-LEcta in 2018 as CFO and managing director. Previously he worked for a private equity owned operator of rehabilitation clinics in Berlin as well as for a family owned integrated healthcare group and was responsible for M&A respectively for corporate finance and investor relations. Before that he gained experiences as banker and consultant with a strong focus on the healthcare sector. Thomas studied business administration at Goethe University in Frankfurt/M and at University of Southampton/UK.
Follow Thomas Pfaadt:
About c-LEcta: c-LEcta operates as a biotechnology company focusing on enzyme engineering and bioprocess development for regulated markets.
Jaska Harm
CFO of LXP Group GmbH
Jaska H. Harm is the CFO of maxbiogas GmbH, a biotech energy startup based in the region Berlin-Brandenburg. With its pre-treatment-process maxbiogas offers an unique state-of-the-art solution to separate efficiently lignin and cellulose from plant residues. At maxbiogas Jaska is in charge of business development, financials and fundraising. Prior to this he has been an advisor in the international real estate and energy industry for almost 20 years. Among other he has founded and managed a district heat supplier and has been advising German and US based open and closed end funds as well as international family offices in all kind of phases in the life cycle of an investment. He holds a Masters Degree in Business from the University of Saarland in Southern Germany and speaks fluently German, Finnish, English, and some Swedish.
Follow Jaska Harm:
About LXP Group GmbH, Maxbiogas: Revolutionary process for utilization of 2G biomass
Thomas Taapken
CFO of InflaRx
Follow Thomas Taapken:
About InflaRx: InflaRx develops new therapeutics in the field of acute and chronic inflammation.
Manfred Bender
Chief Financial Officer of BRAIN
Before joining BRAIN AG, Manfred Bender spent almost 20 years in various senior management positions at Pfeiffer Vacuum Technology AG, a publicly listed company headquartered in Asslar, Germany. For a period of more than three years he acted as the company’s Chief Financial Officer (CFO) prior to assuming the position of Chief Executive Officer (CEO) from July 2007 to November 2017. In this position, Manfred Bender successfully focused on continuously growing the technology company in regard to sales, EBIT, and market capitalization as well as on establishing PFV as a global player operating international production facilities and maintaining a worldwide sales organization. Manfred Bender holds a degree in Business Administration (Diplom-Betriebswirt) from the University of Applied Sciences in Giessen, Germany, and started his career at Schunk GmbH, likewise based in Giessen. Currently he serves as Chairman of the Supervisory Board of Schunk GmbH and is a member of the Supervisory Board of the Volksbank Heuchelheim eG cooperative bank. Manfred Bender was appointed to the Management Board of BRAIN AG with effect from December 1, 2018 and will take over as Chief Financial Officer (CFO) of the company on January 1, 2019.
Follow Manfred Bender:
About BRAIN: BRAIN provides biodiversity-based solutions for applications in the chemical, pharmaceutical, cosmetics and food industries.
Philipp Naegelein
Co-Founder and CFO of MEDIKURA
Follow Philipp Naegelein:
About MEDIKURA: MEDIKURA develops digital infrastructure for drug safety. The goal is to make the drug safety as safe as possible.
Gerrit Maass
CFO of Pantherna Therapeutics
Follow Gerrit Maass:
About Pantherna Therapeutics: Pantherna Therapeutics is a privately-held biopharmaceutical company.
Gerrit Maass
CFO of Pantherna Therapeutics
Follow Gerrit Maass:
About Pantherna Therapeutics: Pantherna Therapeutics is a privately-held biopharmaceutical company.
Philipp Bürling
CFO and Managing Director of Numaferm
Philipp graduated in Business & IT Management at the University of Cooperative Education in Mannheim. He held several management positions in the logistics industry and gained wide experience in general management and project management. Philipp is CFO and co-founder of NUMAFERM. He joined the spin-off project in late 2015.
Follow Philipp Bürling:
About Numaferm: Numaferm is a Dusseldorf University spin-off that specializes in the biotechnical production.
Abdelghani Omari
Chief Financial Officer of Paion
Abdelghani Omari joined PAION in 2008 as Vice President Finance. In 2014 he was appointed Chief Financial Officer of PAION AG. Abdel has more than 17 years of experience in Finance. At KPMG, he adviced international clients on accounting, post-merger integration and financial reporting. Previously, he worked several years in the audit department of KPMG with a focus on the chemical industry. Abdel has been instrumental in PAION’s recent financing and partnering deals. He holds a degree in Business Administration from the University of Aachen.
Follow Abdelghani Omari:
About Paion: PAION is a biopharmaceutical company developing and commercializing drug candidates for diseases with substantial unmet medical needs.
Marcus Irsfeld
Chief Financial Officer of IOmx Therapeutics
Marcus is the Chief Financial Officer. He has a long-standing track record in this position either as employee or freelancer in the life science industry. Over the last years, he has been supporting several biotech and MedTech companies in different maturity stages. In 2001, he started his career in the life science industry as CFO of ProCorde GmbH which merged with Trigen in 2006. He finally took over the responsibility for the whole Trigen Group as the sole member of the executive board of Trigen Holdings AG. Before joining ProCorde, Marcus worked in different industries, including financial controller in a German Chinese joint venture in the province Shandong in China. Marcus holds a degree in Business Administration from the University in Münster, Germany. Marcus was co-founder and CFO of Averitas Pharma Inc. (NJ) which was successfully sold to Gruenenthal.
Follow Marcus Irsfeld:
About IOmx Therapeutics: iOmx Therapeutics focuses on the development of first-in-class cancer therapeutics.